10-Q: Geron Reports Q3 2024 Results, Highlights RYTELO Launch and Secures Financing

Geron Corporation announces its Q3 2024 financial results, marked by the initial commercial launch of RYTELO and strategic financing agreements to support ongoing operations and development.

Summary

• Geron Corporation reported a net loss of $26.4 million for the three months ended September 30, 2024, and $149.2 million for the nine months ended September 30, 2024.
• Product revenue, net from RYTELO sales, which began in June 2024, was $28.2 million for the quarter and $29.0 million for the nine-month period.
• Research and development expenses decreased to $20.2 million for the quarter and $80.3 million for the nine-month period, primarily due to capitalizing manufacturing costs after RYTELO's FDA approval.
• Selling, general and administrative expenses increased to $35.9 million for the quarter and $102.4 million for the nine-month period, reflecting higher personnel-related expenses.
• The company entered into a loan agreement with BioPharma Credit for up to $250 million and a revenue participation right purchase agreement with Royalty Pharma for $125 million in November 2024.
• Geron repaid all obligations under the Hercules Loan Agreement in full on November 1, 2024.
• As of September 30, 2024, Geron had approximately $378.9 million in cash, cash equivalents, restricted cash and marketable securities.
• The company expects the interim analysis for overall survival in the IMpactMF trial may occur in early 2026, and the final analysis may occur in early 2027.
• Geron believes its existing financial resources, together with anticipated revenues from RYTELO sales, will be sufficient to fund projected operating requirements for at least the next 12 months.

Sentiment

Score: 7

Explanation: The sentiment is cautiously optimistic. The FDA approval and initial sales of RYTELO are positive, as are the new financing agreements. However, the company continues to operate at a loss, and the commercial potential of RYTELO remains unproven. The company is also subject to various risks and uncertainties.

Positives

• RYTELO's commercial launch generated $28.2 million in product revenue in Q3 2024.
• The new financing agreements with BioPharma Credit and Royalty Pharma strengthen Geron's financial position.
• The IMpactMF trial is progressing with approximately 70% enrollment.
• The company received a permanent J-code for RYTELO, facilitating reimbursement.
• Geron expects to complete review of the MAA by the Committee for Medicinal Products for Human Use, or CHMP, could be completed in late 2024 or early 2025, with a potential approval decision by the European Commission in the first half of 2025.

Negatives

• Geron continues to operate at a net loss, with $26.4 million loss in Q3 2024.
• Selling, general and administrative expenses increased significantly, impacting profitability.
• The commercial potential of RYTELO and the ability to successfully commercialize RYTELO is unproven.

Risks

• The commercial potential of RYTELO is unproven, and the company has limited experience as a commercial entity.
• The company's reliance on third-party manufacturers and distributors poses supply chain risks.
• Clinical trials are subject to delays and regulatory hurdles.
• The company may require additional funding, which may not be available on acceptable terms.
• The company is subject to compliance with healthcare laws and regulations.
• The company is subject to risks related to information technology systems, data security and data privacy.

Future Outlook

Geron believes its existing financial resources, together with anticipated revenues from RYTELO sales, will be sufficient to fund projected operating requirements for at least the next 12 months. The company plans to support the commercial launch of RYTELO in the U.S. and potentially in the EU, complete the Phase 3 IMpactMF trial, invest in supply chain redundancy for RYTELO, and fund general working capital requirements.

Management Comments

• Based on our current operating plans and assumptions, we believe that our existing cash, cash equivalents, and marketable securities (including the $250 million received under the Pharmakon Loan Agreement and the Royalty Pharma Agreement), together with anticipated revenues from U.S. sales of RYTELO, will be sufficient to fund our projected operating requirements for at least the next 12 months from the date of this filing.
• We believe that our projected financial resources will be sufficient to (i) support commercial launch of RYTELO in the U.S. and potential launch in the EU, (ii) complete the Phase 3 IMpactMF trial in relapsed/refractory MF, (iii) invest in supply chain redundancy for RYTELO, and (iv) fund our general working capital requirements.

Industry Context

Geron is operating in the competitive biopharmaceutical industry, focusing on hematologic malignancies. The company's success depends on its ability to effectively commercialize RYTELO and navigate the regulatory landscape, while also managing competition from established pharmaceutical companies and emerging therapies.

Comparison to Industry Standards

• Geron's reliance on third-party manufacturers is a common practice in the biopharmaceutical industry, but it introduces supply chain risks that must be carefully managed.
• The company's approach to securing financing through debt and revenue participation agreements is a strategy employed by other companies in the sector to fund development and commercialization activities.
• Geron's focus on orphan drug designations and regulatory exclusivity is a common strategy to protect its market position and maximize revenue potential.
• Geron's competitors include companies like Bristol Myers Squibb, Novartis, and AbbVie, which have established positions in the hematology market.
• Comparable companies in the space include Kura Oncology, Disc Medicine, and Sierra Oncology.

Stakeholder Impact

• Shareholders: Potential for increased value through successful commercialization and development of RYTELO.
• Employees: Job security and potential for career growth within the company.
• Patients: Access to a new treatment option for lower-risk MDS.
• Creditors: Repayment of debt obligations and potential for future financing opportunities.

Next Steps

• Continue commercial launch of RYTELO in the U.S.
• Pursue regulatory approval for RYTELO in the EU.
• Advance the IMpactMF trial to interim and final analysis.
• Invest in supply chain redundancy for RYTELO.

Key Dates

Keywords

RYTELO, imetelstat, myelodysplastic syndromes, myelofibrosis, clinical trial, FDA approval, financial results, Geron, revenue, financing